Literature DB >> 19448403

Nuclear receptors: genomic and non-genomic effects converge.

Paloma Ordóñez-Morán1, Alberto Muñoz.   

Abstract

The nuclear receptor superfamily mediates the regulatory activities of many hormones, nutrients and metabolites on the homeostasis and physiology of cells and tissues. Classically, ligand binding induced the ability of nuclear receptors to modulate the transcription rate of target genes (genomic effects), which led to consider them as ligand-activated transcription factors. Later, rapid actions of nuclear receptor ligands were reported that did not involve changes in gene expression. These (non-genomic) effects have been attributed in some cases to receptors different to those mediating gene transcription but most evidences indicate that they result from the activity of a population of nuclear receptor molecules acting outside the cell nucleus. Recent studies on estrogen and vitamin D, and their receptors (ERalpha/beta, VDR) support now the idea that non-genomic and genomic effects may integrate in a unique mode of action of nuclear receptor ligands, in which the non-genomic effects constitute signaling pathways required for the effects at the genome level. Here, we will discuss these novel findings and also those indicating transcriptional regulation through ligand-dependent and -independent crosstalk of nuclear receptors with beta-catenin or VDR-interacting repressor (VDIR).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448403     DOI: 10.4161/cc.8.11.8579

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  42 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

2.  Phosphorylated Nuclear Receptor CAR Forms a Homodimer To Repress Its Constitutive Activity for Ligand Activation.

Authors:  Ryota Shizu; Makoto Osabe; Lalith Perera; Rick Moore; Tatsuya Sueyoshi; Masahiko Negishi
Journal:  Mol Cell Biol       Date:  2017-05-02       Impact factor: 4.272

3.  Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter.

Authors:  V Bartella; P Rizza; I Barone; D Zito; F Giordano; C Giordano; S Catalano; L Mauro; D Sisci; M L Panno; S A W Fuqua; S Andò
Journal:  Breast Cancer Res Treat       Date:  2012-05-24       Impact factor: 4.872

Review 4.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

5.  Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells.

Authors:  Michael W Bronson; Sara Hillenmeyer; Richard W Park; Alexander S Brodsky
Journal:  Mol Endocrinol       Date:  2010-04-14

Review 6.  Insights into rapid modulation of neuroplasticity by brain estrogens.

Authors:  Deepak P Srivastava; Kevin M Woolfrey; Peter Penzes
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

7.  Estrogen Modulates ubc9 Expression and Synaptic Redistribution in the Brain of APP/PS1 Mice and Cortical Neurons.

Authors:  Yu-Jie Lai; Lu Liu; Xiao-Tong Hu; Ling He; Guo-Jun Chen
Journal:  J Mol Neurosci       Date:  2017-02-01       Impact factor: 3.444

8.  Significance of estrogen receptor subtypes in breast tumorigenesis and progression.

Authors:  Weiliang Sun; Chijiang Gu; Minming Xia; Guoping Zhong; Haojun Song; Junming Guo
Journal:  Tumour Biol       Date:  2014-06-11

Review 9.  Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling.

Authors:  Silvia C Resta
Journal:  J Physiol       Date:  2009-07-13       Impact factor: 5.182

10.  Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme.

Authors:  Débora G Salomón; María E Fermento; Norberto A Gandini; María J Ferronato; Julián Arévalo; Jorge Blasco; Nancy C Andrés; Jean C Zenklusen; Alejandro C Curino; María M Facchinetti
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.